N@N

Eun Yang Upgraded (BPMC) to Strong Buy and Decreased Target to $78 on, Jun 1st, 2022

Eun Yang of Jefferies, Upgraded "Blueprint Medicines Corporation" (BPMC) to Strong Buy and Decreased Target from $88 to $78 on, Jun 1st, 2022.

Eun has made no other calls on BPMC in the last 4 months.

There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 4 agree with Eun's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022
• David Lebowitz of "Citigroup" Maintained at Hold with Decreased Target to $68 on, Wednesday, April 13th, 2022
• Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
• David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022

These are the ratings of the 2 analyists that currently disagree with Eun

---

• Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022

Contributing Sources

---